ExpansionJul 2, 2026, 08:01 AM
YD Bio Affiliate Expands Lab Licenses to 46 States
AI Summary
YD Bio announced that its affiliate, EG BioMed US Inc., has secured out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania. This expansion extends the company's CLIA-certified, CAP-accredited laboratory's operating footprint to 46 U.S. states, Washington, D.C., and Guam, significantly broadening patient access for early cancer detection services. The new licenses reinforce YD Bio's transition to a platform-based biotechnology company and support its blood-based testing services for various cancers. The company also noted its ongoing non-binding Memorandum of Understanding to merge with EG BioMed, anticipated to close in 2026.
Key Highlights
- EG BioMed US obtained clinical laboratory licenses in Rhode Island and Pennsylvania.
- Rhode Island license issued May 13, 2026, covers clinical genetics specialty.
- Pennsylvania permit issued June 9, 2026, covers clinical chemistry and hematology.
- Laboratory's authorized multi-state operating footprint now extends to 46 U.S. states, plus D.C. and Guam.
- Expansion broadens patient access and supports early cancer detection operations.
- Laboratory is CLIA-certified and CAP-accredited in Bothell, Washington (CLIA #50D2316600).
- Supports blood-based testing for pancreatic, colorectal, breast, liver, and other GI cancers.
- YD Bio has a non-binding MoU to merge with EG BioMed, anticipated to close in 2026.
Price Impact
More from YDES